 |
| Gadovist® |   |
| |
|
Gadovist® is an extracellular, neutral macrocyclic (gadolinium (Gd) complex) MRI contrast agents for central nervous system indications, particularly suited for studies in which high doses are required or advantageous.
Gadovist® (also Gadograf) was available in two concentrations, currently only Gadovist® 1.0 is marketed.
The product was approved in Switzerland in 1999 and in Germany in 2000. Gadovist® 1.0 is in USA currently in the drug development and approval process, particularly for magnetic resonance angiography.
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
See also Paramagnetic Contrast Agents and Gadobutrol.
|
|
Drug Information and Specification |
| NAME OF COMPOUND |
Gadobutrol, Gd-BT-DO3A
|
| DEVELOPER |
Bayer Schering Pharma AG
|
| CENTRAL MOIETY |
Gd2+ |
| CONTRAST EFFECT |
T1, Predominantly positive enhancement |
| RELAXIVITY |
r1=3.6, B0=1.0 T |
| PHARMACOKINETIC |
Intravascular, extracellular, renal excretion |
| OSMOLALITY |
557 and 1603 mosm/kgH2O |
| CONCENTRATION |
1 mol/L |
| DOSAGE |
0.1mmol/kg |
| PREPARATION |
Finished product |
| INDICATION |
Central nervous system / whole body |
| DEVELOPMENT STAGE |
For sale / submit for approval |
| DISTRIBUTOR |
See below |
| PRESENTATION |
Vials of 15, 30 mL |
| DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT! |
|
|
| |
 |
|
 Further Reading: |
Basics:
|
|
News & More:
| | | | |
] and 1 definition [
]
bottom
(.pdf)
Random Page
top
